Hans-Peter Gerber

Directeur Technique/Scientifique/R&D chez SUTRO BIOPHARMA, INC.

Fortune : - $ au 30/04/2024

61 ans

Health Technology

Consumer Services

Postes actifs de Hans-Peter Gerber

Sociétés	Poste	Début	Fin
SUTRO BIOPHARMA, INC.	Directeur Technique/Scientifique/R&D	18/09/2023	-
T-CURX GmbH	Président	-	-

Sociétés	Poste	Début	Fin
NBE-Therapeutics AG NBE-Therapeutics AG BiotechnologyHealth Technology NBE-Therapeutics AG operates as biotechnology company. It develops next-generation ADCs improving treatment options for cancer patients. The company was founded by Ulf Grawunder in 2012 and is based in Basel, Swizerland.	Directeur/Membre du Conseil	01/01/2017	01/01/2021
	Independent Dir/Board Member	01/01/2017	01/01/2021
Maverick Therapeutics, Inc. Maverick Therapeutics, Inc. BiotechnologyHealth Technology Maverick Therapeutics, Inc. operates as a preclinical stage biotech company. It develops a novel class of T cell- redirecting antibody therapeutics that have the potential to substantially broaden the range of targets and clinical applications to be used for this ultra-potent mechanism. The company was founded by Robert Dubridge and Patrick A. Baeuerle in 2016 and is headquartered in Brisbane, CA.	Directeur/Membre du Conseil	01/01/2016	01/01/2018
	President	01/01/2016	01/01/2018

University of Zurich

Doctorate Degree

Internationale

Opérationnelle

Director/Board Member	2
President	1
Independent Dir/Board Member	1

Sectorielle

Health Technology	4
Consumer Services	2

Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Sociétés cotées	1
SUTRO BIOPHARMA, INC.	Health Technology

Entreprise privées	3
NBE-Therapeutics AG NBE-Therapeutics AG BiotechnologyHealth Technology NBE-Therapeutics AG operates as biotechnology company. It develops next-generation ADCs improving treatment options for cancer patients. The company was founded by Ulf Grawunder in 2012 and is based in Basel, Swizerland.	Health Technology
Maverick Therapeutics, Inc. Maverick Therapeutics, Inc. BiotechnologyHealth Technology Maverick Therapeutics, Inc. operates as a preclinical stage biotech company. It develops a novel class of T cell- redirecting antibody therapeutics that have the potential to substantially broaden the range of targets and clinical applications to be used for this ultra-potent mechanism. The company was founded by Robert Dubridge and Patrick A. Baeuerle in 2016 and is headquartered in Brisbane, CA.	Health Technology
T-CURX GmbH